Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients
Autor:
Christopher Wills, Katie Watts, Victoria Gray, Valentina Escott-Price, David J. Kerr, Hannah West, Claire Palles, Richard Kaplan, Nada Al-Tassan, Ayman Madi, Tim Maughan, Rachel Kerr, Jeremy Peter Cheadle, Richard S. Houlston
Publikováno v:
International Journal of Cancer. 149:1713-1722
Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sou
Autor:
Jos H. Beijnen, Alwin D. R. Huitema, Philip C. Schouten, Sabine C. Linn, Jan H.M. Schellens, Katarzyna Jóźwiak, Serena Marchetti, Gwen M. H. E. Dackus, Jill J.J. Geenen, Gabe S. Sonke, Dick Pluim
Publikováno v:
International Journal of Cancer
Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olapa
Autor:
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Thao Dang, Sara Sadowski, Debra A. Kush, Yu Zhou, Ben Li, Tony Mok
Publikováno v:
International Journal of Cancer
In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/meta
Autor:
Carla Verena Hannig, Thomas R. W. Herrmann, Lukas Perkhofer, Thomas J. Ettrich, Thomas Seufferlein, Petra Büchner-Steudel, Andreas Berger, Patrick C. Hermann, Holger Hebart, Thomas J. Hoffmann, Thomas Decker, Volker Heinemann, M Güthle, Ralf-Dieter Hofheinz
Publikováno v:
International Journal of Cancer. 148:1428-1437
Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-3 and platelet-derived growth factor receptor-a/-b. Thereby, it targets angiogenic escape mechanisms. The trial TyRos
Autor:
Peter J. Goebell, Michael Staehler, Norbert Marschner, Till‐Oliver Emde, Lisa Kruggel, Martina Jänicke, Natalie Wetzel, Lothar Müller
Publikováno v:
International Journal of Cancer
Non‐clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, tr
Autor:
Ho Sup Lee, Yeon-Joo Song, Won Sik Lee, Jae-Cheol Jo, Min-Jung Kim, Da Jung Kim, Lee Chun Park, Ho-Jin Shin, Young Rok Do, Sung Yong Oh, Jee-Yeong Jeong
Publikováno v:
International Journal of Cancer. 145:2459-2467
Erythropoiesis-stimulating agents (ESAs), such as erythropoietin (EPO) and darbepoetin, may alleviate anemia in diffuse large B-cell lymphoma (DLBCL) patients. However, many cancer cells express EPO receptors (EPOR), through which exogenously adminis
Publikováno v:
International Journal of Cancer. 146:1457-1467
It remains unclear whether there is a relationship between therapeutic effects of hypomethylating agents (HMAs) and epigenetic modifier gene mutations (EMMs) in patients with cytogenetically intermediate-risk acute myeloid leukemia (IR-AML). Based on
Autor:
Ming Huang Hong, Hai Qiang Mai, Ming Yuan Chen, Ting Kang, Rui You, Wan Li Liu, Xiong Zou, Yi Nuan Zhang, Pei Yu Huang, Wei Bang Guo, Ai Hua Lin, Ke Ming Zhao, Li Zhi Liu, Mei Lin, Mu Sheng Zeng, You Ping Liu, Lin Quan Tang, Yi Pan
Publikováno v:
International Journal of Cancer. 145:2873-2883
We analyzed the number of circulating tumor cells (CTCs) and Epstein-Barr virus DNA (EBV DNA) for diagnosis, monitoring and prognosis of patients with metastatic nasopharyngeal carcinoma (mNPC). The levels of CTCs and EBV DNA were measured at baselin